EP4731793A2 — Compositions comprising antineoplastons and methods of treating pancreatic cancer
Assigned to Individual · Expires 2026-04-29 · 0y expired
What this patent protects
Disclosed herein are compositions comprising one or more antineoplastons and using those compositions in methods of treating pancreatic cancer, prolonging the survival of a subject, and preventing and/or decreasing metastasis of pancreatic cancer.
USPTO Abstract
Disclosed herein are compositions comprising one or more antineoplastons and using those compositions in methods of treating pancreatic cancer, prolonging the survival of a subject, and preventing and/or decreasing metastasis of pancreatic cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.